Ophthotech Corporation to Present at the 2014 Barclays Capital Global Healthcare Conference
Webcast Available Through Ophthotech Website
NEW YORK--(BUSINESS WIRE)--
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R.
Guyer, M.D., Chief Executive Officer and Chairman of the Board, will
present an overview of the Company at the Barclays Capital Global
Healthcare Conference in Miami on Tuesday, March 11, 2014 at 9:30 a.m.
Investors and the general public are invited to listen to a live webcast
of the presentation at www.ophthotech.com.
Please connect to Ophthotech's website several minutes prior to the
start of the presentation to ensure adequate time for any software
download that may be necessary. A replay will be available for 14 days
following the presentation.
Ophthotech is a biopharmaceutical company specializing in the
development of novel therapeutics to treat diseases of the eye, with a
focus on developing innovative therapies for age-related macular
degeneration (AMD). Ophthotech's most advanced product candidate,
Fovista™ anti-PDGF therapy, is in Phase 3 clinical trials for use in
combination with anti-VEGF drugs that represent the standard of care for
the treatment of wet AMD. The Company's second product candidate
Zimura™, an inhibitor of complement factor C5, is being developed for
the treatment of dry and wet forms of AMD. For more information, please
Any statements in this press release about Ophthotech's future
expectations, plans and prospects constitute forward-looking statements
for purposes of the safe harbor provisions under the Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors. Any forward-looking statements represent
Ophthotech's views only as of the date of this press release. Ophthotech
anticipates that subsequent events and developments will cause its views
to change. While Ophthotech may elect to update these forward-looking
statements at some point in the future, Ophthotech specifically
disclaims any obligation to do so.
Vice President, Investor Relations and Corporate
LLC on behalf of Ophthotech Corporation
Jarrod Aldom, 973-442-1555
Source: Ophthotech Corporation
News Provided by Acquire Media